Cargando…

Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems

Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ine...

Descripción completa

Detalles Bibliográficos
Autores principales: Baryakova, Tsvetelina H., Pogostin, Brett H., Langer, Robert, McHugh, Kevin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041531/
https://www.ncbi.nlm.nih.gov/pubmed/36973491
http://dx.doi.org/10.1038/s41573-023-00670-0
_version_ 1784912740547035136
author Baryakova, Tsvetelina H.
Pogostin, Brett H.
Langer, Robert
McHugh, Kevin J.
author_facet Baryakova, Tsvetelina H.
Pogostin, Brett H.
Langer, Robert
McHugh, Kevin J.
author_sort Baryakova, Tsvetelina H.
collection PubMed
description Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ineffective. Formulating a pharmaceutical in a drug delivery system (DDS) is a promising alternative that can directly mitigate many common impediments to adherence, including frequent dosing, adverse effects and a delayed onset of action. Existing DDSs have already positively influenced patient acceptability and improved rates of adherence across various disease and intervention types. The next generation of systems have the potential to instate an even more radical paradigm shift by, for example, permitting oral delivery of biomacromolecules, allowing for autonomous dose regulation and enabling several doses to be mimicked with a single administration. Their success, however, is contingent on their ability to address the problems that have made DDSs unsuccessful in the past.
format Online
Article
Text
id pubmed-10041531
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-100415312023-03-27 Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems Baryakova, Tsvetelina H. Pogostin, Brett H. Langer, Robert McHugh, Kevin J. Nat Rev Drug Discov Review Article Poor medication adherence is a pervasive issue with considerable health and socioeconomic consequences. Although the underlying reasons are generally understood, traditional intervention strategies rooted in patient-centric education and empowerment have proved to be prohibitively complex and/or ineffective. Formulating a pharmaceutical in a drug delivery system (DDS) is a promising alternative that can directly mitigate many common impediments to adherence, including frequent dosing, adverse effects and a delayed onset of action. Existing DDSs have already positively influenced patient acceptability and improved rates of adherence across various disease and intervention types. The next generation of systems have the potential to instate an even more radical paradigm shift by, for example, permitting oral delivery of biomacromolecules, allowing for autonomous dose regulation and enabling several doses to be mimicked with a single administration. Their success, however, is contingent on their ability to address the problems that have made DDSs unsuccessful in the past. Nature Publishing Group UK 2023-03-27 2023 /pmc/articles/PMC10041531/ /pubmed/36973491 http://dx.doi.org/10.1038/s41573-023-00670-0 Text en © Springer Nature Limited 2023, Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Review Article
Baryakova, Tsvetelina H.
Pogostin, Brett H.
Langer, Robert
McHugh, Kevin J.
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
title Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
title_full Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
title_fullStr Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
title_full_unstemmed Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
title_short Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
title_sort overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10041531/
https://www.ncbi.nlm.nih.gov/pubmed/36973491
http://dx.doi.org/10.1038/s41573-023-00670-0
work_keys_str_mv AT baryakovatsvetelinah overcomingbarrierstopatientadherencethecasefordevelopinginnovativedrugdeliverysystems
AT pogostinbretth overcomingbarrierstopatientadherencethecasefordevelopinginnovativedrugdeliverysystems
AT langerrobert overcomingbarrierstopatientadherencethecasefordevelopinginnovativedrugdeliverysystems
AT mchughkevinj overcomingbarrierstopatientadherencethecasefordevelopinginnovativedrugdeliverysystems